| Similar Articles |
 |
The Motley Fool June 28, 2005 Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever.  |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?  |
The Motley Fool January 5, 2004 Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales.  |
The Motley Fool October 5, 2007 Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition.  |
The Motley Fool March 28, 2005 Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen?  |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers.  |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground.  |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector.  |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down.  |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.  |
The Motley Fool January 4, 2008 Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December.  |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition.  |
The Motley Fool January 3, 2006 Stephen D. Simpson |
Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures.  |
The Motley Fool March 22, 2004 Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.  |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note.  |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's...  |
The Motley Fool July 6, 2007 Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.  |
The Motley Fool August 15, 2005 Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors.  |
The Motley Fool June 21, 2004 Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.  |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note.  |
The Motley Fool January 4, 2005 Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship.  |
The Motley Fool December 21, 2007 Timothy M. Otte |
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales.  |
The Motley Fool March 26, 2007 Ryan Fuhrmann |
Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note.  |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%.  |
The Motley Fool October 8, 2011 Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide.  |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note.  |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition.  |
The Motley Fool March 24, 2011 Rick Aristotle Munarriz |
It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak.  |
The Motley Fool May 8, 2007 Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.  |
The Motley Fool April 8, 2004 Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line.  |
The Motley Fool September 27, 2007 Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired.  |
The Motley Fool October 4, 2005 Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space.  |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine?  |
The Motley Fool October 6, 2004 Steven Mallas |
Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage.  |
The Motley Fool September 28, 2007 Timothy M. Otte |
Foolish Forecast: Walgreen Still Minting the Green? In advance of fourth-quarter earnings, analysts expect the company to continue its record of four straight years of sales growth.  |
The Motley Fool March 27, 2006 Jeremy MacNealy |
Just What the Doctor Ordered Walgreen continues to shine as pharmacy sales remain healthy. Investors, take note.  |
The Motley Fool September 27, 2004 Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27.  |
The Motley Fool January 3, 2012 Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses.  |
The Motley Fool January 9, 2006 Rick Aristotle Munarriz |
3 Stocks That Blew the Market Away Beat the market and the world will beat a path to your door: Constellation Brands... Monsanto... Walgreen...  |
The Motley Fool January 3, 2012 Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts.  |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them.  |
The Motley Fool May 9, 2005 Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note.  |
The Motley Fool March 24, 2008 Timothy M. Otte |
Expecting More From Walgreen The drugstore giant has managed to beat analyst estimates two quarters in a row, but earnings are lagging sales growth, and growth is slowing too.  |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.  |
The Motley Fool June 25, 2007 Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see.  |
The Motley Fool November 8, 2006 Michael P. Cecil |
CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm.  |
The Motley Fool October 2, 2007 Lawrence A. Rothman |
Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future.  |
The Motley Fool March 23, 2011 Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount.  |
The Motley Fool February 4, 2005 Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it.  |
The Motley Fool June 14, 2010 Rich Smith |
Is CVS' $2 Billion Buyback Good Medicine? Don't assume just because CVS is buying its stock, that this is a good idea.  |